Sep 2026
Pharmacological inhibition of CBP sensitizes breast cancer to DNA-damaging agents by compromising DNA repair and cell cycle pathways.
In vitro and in vivo breast cancer models show that CBP inhibition disrupts DNA repair and cell-cycle regulatory pathways, thereby enhancing doxorubicin-induced cytotoxicity and apoptosis, and support a rational epigenetic-chemotherapy combination approach.
Wafaa S. Ramadan, Iman M. Talaat, A. Al-Azawi et al.
· Translational Research: The... · 0 citations